On July 13, 2026, Autonomix Medical, Inc. entered into a warrant inducement agreement with a holder of Series C warrants issued on November 19, 2025. The company reduced the exercise price of 428,731 existing warrants to $6.00 per share, expecting aggregate gross proceeds of approximately $2.6 million. In exchange, the company issued two new unregistered warrants (Series D-1 and Series D-2), each allowing the purchase of 428,731 shares at an exercise price of $5.75 per share with a 5.5-year term. Maxim Group LLC served as the solicitation agent and will receive a cash fee of 7.0% of the total proceeds plus expenses up to $15,000. Autonomix Medical is a medical device company that develops precision nerve-targeted treatments for diseases involving the nervous system.
